Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 November 2004

Angiotensin II and its fragments (angiotensins III and IV) decrease the growth of DU-145 prostate cancer in vitro.

Hanna Ławnicka, Agnieszka M. Potocka, Alina Juzala, Marie Claude Fournie-Zaluski, Marek Pawlikowski

Med Sci Monit 2004; 10(11): BR410-413 :: ID: 11805


BACKGROUND: There is growing evidence that angiotensin II (AngII) and its smaller fragments 2-8 (AngIII) and 3-8 (AngIV) are involved in cell-growth control in the vascular smooth muscle and in some other tissues, including prostate. The aim of this paper was to investigate the effects of AngII and its fragments AngIII and AngIV on the growth of an androgen-independent human prostate cancer cell line in vitro. To see whether the conversion of Ang II into its shorter fragments plays a role in the action of the former, we used specific inhibitors of aminopeptidases: compound EC33 (inhibitor of aminopeptidase A), which blocks the conversion of AngII into AngIII, and compound PC 18 (inhibitor of aminopeptidase N), which blocks the conversion of AngIII into AngIV. MATERIAL/METHODS: Human prostate cancer DU-145 cells were exposed in culture to different concentrations of AngII, AngIII, and AngIV separately or jointly with the aminopeptidase inhibitors EC33 or PC18. To measure cell growth, the colorimetric method, based on the reduction of tetrazolium salt by viable cells, was applied. RESULTS: It was found that exposure of DU-145 cells in vitro to all the investigated angiotensins resulted in a moderate, concentration-dependent inhibition of cell growth. The joint exposure of DU-145 cells to AngII plus EC33, but not to AngII plus PC 18, abolished the effect of AngII. CONCLUSIONS: These findings suggest that angiotensin peptides (AngII as well as its smaller fragments) are involved in the negative control of prostate cancer cell growth.

Keywords: Angiotensin II - analogs & derivatives, Angiotensin II - therapeutic use, Angiotensin III - therapeutic use, Glutamyl Aminopeptidase - antagonists & inhibitors, Sulfonic Acids - pharmacology, Angiotensin II - therapeutic use, Angiotensin III - therapeutic use, Glutamyl Aminopeptidase - antagonists & inhibitors, Prostatic Neoplasms - drug therapy, Sulfonic Acids - pharmacology

Add Comment 0 Comments


01 June 2024 : Editorial  

Editorial: Concerns as Highly Pathogenic Avian Influenza (HPAI) Virus of the H5N1 Subtype is Identified in Dairy Cows and Other Mammals

Dinah V. Parums

DOI: 10.12659/MSM.945315

Med Sci Monit 2024; 30:e945315


In Press

Clinical Research  

Trust and Support for Cancer Research Biobanks: Insights from Cancer Patients in Poland

Med Sci Monit In Press; DOI: 10.12659/MSM.944263  

Clinical Research  

Morphological and Dimensional Analysis of the Nasopalatine Canal: Insights from Cone-Beam Computed Tomograp...

Med Sci Monit In Press; DOI: 10.12659/MSM.944424  

Clinical Research  

Hemorrhagic Cysts in the Pancreas: Risk Factors, Treatment, and Outcomes – Insights from a Single-Center Study

Med Sci Monit In Press; DOI: 10.12659/MSM.941955  

Clinical Research  

Perioperative Administration of Tranexamic Acid and Low Molecular Weight Heparin for Enhanced Blood Managem...

Med Sci Monit In Press; DOI: 10.12659/MSM.944063  

Most Viewed Current Articles

14 Dec 2022 : Clinical Research   1,421,178

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990


17 Jan 2024 : Review article   1,355,487

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799


16 May 2023 : Clinical Research   690,090

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387


01 Jan 2022 : Editorial   50,113

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952


Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750